drugset / Trial / NCT07377916
Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC
Not yet recruiting
60 enrolled
The First Affiliated Hospital of Guangzhou Medical University
Maoming People's Hospital · collabPeking University Shenzhen Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The study enrolled patients with advanced or metastatic NSCLC harboring HER2 mutations, amplification, or overexpression who had progressed after ≥1 prior lines of anticancer therapy. After enrollment, participants received treatment with rezetamab plus pertuzumab until disease progression, intolerable toxicity, withdrawal of consent, or other conditions requiring treatment discontinuation.
Timeline
- Start
- 2026-02-15
- Primary completion
- 2029-06-30
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pertuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | Intravenous |